1. A RAC-GEF network critical for early intestinal tumourigenesis
- Author
-
Jim Cassidy, Owen J. Sansom, William C. Clark, Luis Serrano, Volker M. Stucke, Martin J Drysdale, Martin R Turner, Arafath Kaja Najumudeen, R.P. Fordham, Karen Pickering, Lucas B. Zeiger, Ewan J. McGhee, Saskia M. Brachmann, Ann Hedley, Andrew D. Campbell, Kathryn Gilroy, Jeanette A. Johansson, Maureen M. Bain, David F. Vincent, Kevin Myant, Christina Kiel, Kurt I. Anderson, Benjamin LeRoy Miller, Angeliki Malliri, S.R. van Hoof, Sigrid K. Fey, Jan Paul Medema, E.B. Unal, Anna-Karin E. Johnsson, Catherine Nixon, Laura M. Machesky, Douglas Strathdee, Center of Experimental and Molecular Medicine, Radiotherapy, CCA - Cancer biology and immunology, Najumudeen, AK [0000-0002-3764-5721], Zeiger, LB [0000-0002-8712-3112], Gay, DM [0000-0002-7407-1245], Machesky, LM [0000-0002-7592-9856], Nixon, C [0000-0002-8085-2160], Johnsson, AE [0000-0002-0018-700X], Strathdee, D [0000-0003-2959-4327], Anderson, KI [0000-0002-9324-9598], Malliri, A [0000-0001-6848-090X], Turner, M [0000-0002-3801-9896], Serrano, L [0000-0002-5276-1392], Myant, K [0000-0001-8017-1093], Campbell, AD [0000-0003-3930-1276], Sansom, OJ [0000-0001-9540-3010], Apollo - University of Cambridge Repository, Najumudeen, A. K. [0000-0002-3764-5721], Zeiger, L. B. [0000-0002-8712-3112], Gay, D. M. [0000-0002-7407-1245], Machesky, L. M. [0000-0002-7592-9856], Nixon, C. [0000-0002-8085-2160], Johnsson, A. E. [0000-0002-0018-700X], Strathdee, D. [0000-0003-2959-4327], Anderson, K. I. [0000-0002-9324-9598], Malliri, A. [0000-0001-6848-090X], Turner, M. [0000-0002-3801-9896], Serrano, L. [0000-0002-5276-1392], Myant, K. [0000-0001-8017-1093], Campbell, A. D. [0000-0003-3930-1276], and Sansom, O. J. [0000-0001-9540-3010]
- Subjects
0301 basic medicine ,VAV3 ,rac1 GTP-Binding Protein ,VAV2 ,Carcinogenesis ,Homeòstasi ,General Physics and Astronomy ,Imaging ,0302 clinical medicine ,Guanine Nucleotide Exchange Factors ,Homeostasis ,T-Lymphoma Invasion and Metastasis-inducing Protein 1 ,Wnt Signaling Pathway ,Mice, Knockout ,Multidisciplinary ,Wnt signaling pathway ,article ,Phenotype ,Up-Regulation ,Colon cancer ,Intestines ,Organ Specificity ,030220 oncology & carcinogenesis ,64/60 ,Signal transduction ,631/67/70 ,Signal Transduction ,Science ,Adenomatous Polyposis Coli Protein ,RAC1 ,13/106 ,631/67/1504/1885/1393 ,Biology ,General Biochemistry, Genetics and Molecular Biology ,38/91 ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,Downregulation and upregulation ,14/33 ,Animals ,Proto-Oncogene Proteins c-vav ,Cancer models ,Tumors ,General Chemistry ,030104 developmental biology ,Mutation ,13/51 ,Cancer research ,Intestins -- Càncer ,Genètica - Abstract
RAC1 activity is critical for intestinal homeostasis, and is required for hyperproliferation driven by loss of the tumour suppressor gene Apc in the murine intestine. To avoid the impact of direct targeting upon homeostasis, we reasoned that indirect targeting of RAC1 via RAC-GEFs might be effective. Transcriptional profiling of Apc deficient intestinal tissue identified Vav3 and Tiam1 as key targets. Deletion of these indicated that while TIAM1 deficiency could suppress Apc-driven hyperproliferation, it had no impact upon tumourigenesis, while VAV3 deficiency had no effect. Intriguingly, deletion of either gene resulted in upregulation of Vav2, with subsequent targeting of all three (Vav2−/− Vav3−/− Tiam1−/−), profoundly suppressing hyperproliferation, tumourigenesis and RAC1 activity, without impacting normal homeostasis. Critically, the observed RAC-GEF dependency was negated by oncogenic KRAS mutation. Together, these data demonstrate that while targeting RAC-GEF molecules may have therapeutic impact at early stages, this benefit may be lost in late stage disease., Loss of small GTPase RAC1 suppresses intestinal tumorigenesis caused by APC loss, but impacts normal intestinal homeostasis. Here, the authors provide an alternative method of reducing RAC1 activity by the combined targeting of three RAC-GEFs and show that this approach delays intestinal tumorigenesis without the detrimental effects on normal intestinal architecture.
- Published
- 2021